Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Earnings Winners And Losers: ATRC, GB, MDT, NVRO, ELGX

This article was originally published in Clinica

Executive Summary

Atricure (ATRC), Greatbatch (GB), Medtronic (MDT), Nevro (NVR), and Endologix (ELGX) were some of the device companies announcing their quarterly results in the last week. We looked at which reported major success, which are struggling, and which deserve more attention in the future.

You may also be interested in...



2019 Device Approvals Review: Original PMAs Up, De Novos Down

The US FDA approved fewer novel devices in 2019 than in 2018, despite a slight increase in original PMA approvals. De novo clearances were down significantly after four straight years of increases, while panel-track PMA supplements and 510(k) clearances also declined from the 2018 totals.

NANS 2020: SPR Therapeutics' Nerve Stimulation System Provides 12-Month Pain Relief After 60-Day Treatment

SPR Therapeutics said its SPRINT neurostimulation technology achieved a 63% reduction in average pain intensity in patients with chronic low back pain.

Abbott Launches REPAIR MR Trial To Bring MitraClip To More Patients

The 500-patient REPAIR MR trial will evaluate Abbott’s MitraClip mitral valve repair device in patients who would face moderate risk during open heart surgery. MitraClip is currently approved only for patients who are not surgical candidates.

Topics

UsernamePublicRestriction

Register

MT103245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel